23 results about "Cardiac conduction" patented technology

Antibodies specific to human contactin2 (CNTN2), and imaging and / or diagnostic reagents and compositions visualizing the CCS cells, therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention.

The invention provides an electrocardio physiological signal feature extraction method for heart conduction block classification, and belongs to the technical field of electrocardio physiological signals. 12-lead electrocardiosignals and auxiliary signals of a patient are collected, a wave equation is established through a water-wave-imitating interference multi-signal fusion algorithm, and a multi-lead signal interference mode is simulated; the method comprises the following steps: extracting time domain characteristic parameters including a PR interval, a QRS wave width, a QT interval and the like from a fusion signal, and calculating frequency domain characteristic parameters including power density distribution and a heart rate variability index; nonlinear dynamic characteristic parameters including a sample entropy value, a fractal dimension and the like are extracted, the conduction block type is judged according to the PR interval length and a QRS wave falling mode, and the technical problem that a weak heart conduction block characteristic signal cannot be accurately recognized through single-lead electrocardio analysis is solved.

Antitachycardia pacing (ATP) therapy may be delivered to the cardiac conduction system using cardiac conduction system pacing therapy. An initial cardiac conduction system ATP pulse set including three or less cardiac conduction system ATP pulses may be delivered to the patient's cardiac conduction system. A first cardiac conduction system ATP pulse of the initial cardiac conduction system ATP pulse set may be delivered at an interval configured to provide maximal capture of the cardiac conduction system.

An implantable medical device includes a plurality of implantable electrodes for sensing and pacing a heart of a patient. The plurality of electrodes includes cardiac conduction system electrodes positionable proximate a portion of a cardiac conduction system of a patient. A computing device includes processing circuitry and is operably coupled to a plurality of implantable electrodes. A computing device monitors a precardiac ejection (HS-PEP) of a heart of a patient. A change in the HS-PEP is determined based on the monitoring. A change in HS-PEP is determined to be greater than or equal to a specified threshold. Delivery of cardiac conduction system pacing therapy to the cardiac conduction system of the patient using the cardiac conduction system electrode is initiated based on the HS-PEP being greater than or equal to a specified threshold.

This article describes systems and methods for determining whether cardiac conduction system pacing therapy may be beneficial and / or for determining how close or far a cardiac conduction system block may be using external cardiac signals. For this purpose, one or more left-sided measures can be generated based on left-sided alternative cardiac electrical activity measured using multiple left external electrodes to produce information on electrical heterogeneity.

The present disclosure includes a lead, a lead delivery system, and a method. The lead delivery system includes a lead body, at least one left bundle branch (LBB) electrode, and an anchoring device. The lead body extends from a proximal end to a distal end, with a penetrating portion of the lead body adjacent to the distal end and configured to extend through and perforate a ventricular septum of a patient's heart to position the distal end adjacent to a left ventricular endocardium of the patient's heart. The LBB electrode is coupled to the lead body adjacent to the distal end of the lead body and is configured to pace a LBB region. The anchoring device is adjacent to the distal end of the lead body and is configured to secure the lead body to the ventricular septum, with the anchoring device configured to adapt from a delivery configuration to an anchoring configuration.

The application relates to a magnetic navigation guiding tearable sheath for heart conduction bundle pacing, which comprises a sheath body and a joint fixedly connected to the rear end of the sheath body, the sheath body comprises a front soft section and a rear fixed section, and the front soft section can be arbitrarily bent; a plurality of pairs of half-ring magnets are arranged on the outer surface of the front soft section close to the head end, two half-ring magnets in each pair of half-ring magnets are symmetrically arranged and form a ring, and a gap is left between the two half-ring magnets; three electrodes are arranged on the head end of the front soft section and are uniformly distributed in the circumferential direction, the three electrodes can be combined in any two, and three electrode pairs for intracardiac potential recording and positioning are formed; each electrode is connected with an electrode lead wire, and the rear end of the sheath body is provided with an electrode tail wire interface, and the other ends of the three electrode lead wires are fixedly arranged in the electrode tail wire interface. The application is beneficial to intracardiac potential recording and positioning, is convenient to contact with the heart cavity, stably adheres to the endocardium, and ensures that the pacing electrode is stably rotated out.

A detachable leadless pacemaker system for cardiac conduction bundle pacing is disclosed. The system includes a detachable leadless pacemaker and a passive leadless pacemaker. A hook-shape side electrode is inserted into a ventricular septum for cardiac conduction bundle pacing. The detachable leadless pacemaker may be arranged in a ventricle, and the passive leadless pacemaker may be arranged in an atrium, so as to realize dual-chamber pacing both in the ventricle and in the atrium. The detachable leadless pacemaker is coupled with the passive leadless pacemaker by an anti-tension reinforced wire, which is used for pulling back the detachable leadless pacemaker to a new position.

Illustrative systems, devices, and methods monitor cardiac morphology during delivery of cardiac conduction system pacing therapy to determine effective cardiac conduction system pacing therapy. If effective cardiac conduction system pacing therapy is not determined, one or both of the cardiac conduction system pacing vector and atrioventricular delay may be adjusted until the monitored cardiac morphology indicates effective cardiac conduction system pacing therapy.

Systems, devices, and methods for delivering conductive nanomaterials to a target location in a patient's heart to affect the patient's heart conduction system, such as delivering conductive nanomaterials into the ventricular septum of the patient's heart to improve an impaired heart conduction pathway, such as the left bundle branch.

The application discloses a detachable leadless pacemaker system which can pace cardiac conduction bundle. The specific embodiment of the system comprises: a detachable leadless pacemaker, the detachable leadless pacemaker is provided with a first data interface; a passive leadless pacemaker, the passive leadless pacemaker is provided with a second data interface; a signal line, which is connected with the first data interface and the second data interface respectively, so as to realize power supply of the detachable leadless pacemaker for the passive leadless pacemaker and data communication between the two. The detachable leadless pacemaker can be arranged in a ventricle to realize atrioventricular dual chamber pacing with the passive leadless pacemaker arranged in an atrium. An unpackaged circuit can be arranged in the passive leadless pacemaker, which is used as an electrode carrier for sensing atrial electrical signals and implementing electrical stimulation. The detachable leadless pacemaker and the passive leadless pacemaker are connected by a tensile-resistant reinforcing line, which is used for recovery operation when the detachable leadless pacemaker is repositioned.

A pacemaker system includes a drive-sense circuit (DSC) operably coupled to a pacemaker lead. The DSC generates a pace signal including electrical impulses based on a reference signal. The DSC provides the pace signal via the pacemaker lead to an electrically responsive portion of a cardiac conductive system of a subject to facilitate cardiac operation of a cardiovascular system of the subject. The DSC senses, via the pacemaker lead, cardiac electrical activity of the cardiovascular system of the subject that is generated in response to the pace signal and electrically coupled into the pacemaker lead and generates a digital signal that is representative of the cardiac electrical activity of the cardiovascular system of the subject that is sensed via the pacemaker lead. The DSC provides digital information to one or more processing modules that includes and / or is coupled to memory and that provide the reference signal to the DSC.

To diagnose an arrhythmia of a patient.SOLUTION: A system 100 for diagnosing an arrhythmia of a patient comprises: a diagnostic catheter 10 for insertion into the heart of the patient, the diagnostic catheter 10 configured to record anatomical and electrical activity data of the patient; and a processing unit. The processing unit is configured to receive the recorded electrical activity data 120, and correlate the electrical activity data 120 with the anatomic data. The processing unit comprises an algorithm configured to analyze the electrical activity at a location correlated with the anatomic data.SELECTED DRAWING: Figure 1

Described herein are systems, methods, and apparatuses for determining capture of a cardiac conduction system by a ventricular to atrial (VfA) therapy. A VfA therapy can be delivered at a plurality of different A-V delays while the electrical activity of a patient is monitored. The electrical activity can then be utilized to determine whether the cardiac conduction system of the patient has been captured by the VfA therapy.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and / or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and / or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

A catheter system for implanting a lead for cardiac conduction system is provided. The catheter system includes a catheter having an orifice extending from a distal end of the catheter to a proximal end of the catheter for implanting the lead, and a probe extending through the catheter. The probe includes a conductive wire covered with an insulation layer. A distal end of the wire is exposed from the insulation layer. The distal end of the wire includes a wire electrode configured to conduct pacing prior to implanting the lead.

Adaptive cardiac conduction system pacing therapy may monitor electrical activity of a patient's heart and select a cardiac conduction system pacing therapy pacing mode based on the monitored electrical activity. For instance, one or more metrics such as P-wave-to-R-wave interval and QRS complex width may be determined based on the monitored electrical activity, and one of an inhibited pacing mode, a ventricular fusion pacing mode, an atrioventricular synchronous pacing mode, and an atrial fibrillation pacing mode may be selected based on the determined one or more metrics.

Systems, devices, and methods for performing cardiac diagnostic procedures are provided herein. A system for locating a segment of a cardiac conduction pathway in a patient includes a plurality of sensors disposed on a surface of a body of the patient; a data collection system to collect sensor data from the plurality of sensors; a data processing system to calculate CEA data from the sensor data; and a display system for presenting a three-dimensional model of positioning of the segment of the cardiac conduction pathway based on the calculated CEA data.

The present disclosure relates to pacing of the cardiac conduction system, and to delivery of an implantable medical device (IMD). A delivery catheter may be configured to deliver the IMD, the delivery catheter including a deployment tube, a handle, a cup, and a sleeve. The deployment tube can define a curve along a portion of a length of the deployment tube, the curve comprising a first shape. The handle can be coupled to the proximal end of the deployment tube and used to control the delivery device. The cup can be coupled to the distal end of the deployment tube and configured to house a leadless implantable medical device. The sleeve can be disposed around the perimeter of the deployment tube, the sleeve configured to move from a first undeployed position to a second deployed position and manipulate the curve from the first shape to a second shape.

To diagnose the patient's arrhythmia. [Solution] The system 100 for diagnosing a patient's arrhythmia is inserted into the patient's heart. A diagnostic catheter 10 for recording the patient's anatomical and electrical activity data. It includes a diagnostic catheter 10 configured as and a processing unit. The processing unit records The system receives the electrical activity data 120 and compares the electrical activity data 120 with the anatomical data. They are configured to be linked together. The processing unit is the position associated with the anatomical data. This includes an algorithm configured to analyze electrical activity.

The present invention provides a method for determining a cardiac conduction velocity, a device using the same, a cardiac 3D structure imaging device and a system for determining a cardiac conduction velocity, and the method is implemented by a processor, comprising receiving heart 3D data including vertex coordinates for a plurality of triangles constituting a heart structure, calculating a normal vector for a target triangle based on the vertex coordinates of the target triangle selected among the plurality of triangles, determining the cardiac conduction velocity for the target triangle based on the normal vector, and determining the cardiac conduction velocity for the target vertex based on a cardiac conduction velocity for an adjacent triangle including the target vertex selected among the vertices of the target triangle among the plurality of triangles.

The invention provides application of calcium dobesilate in preparation of a medicine for treating and / or preventing indoor conduction block caused by diabetes mellitus. The invention provides a non-invasive method capable of actively improving the heart conduction function for treating and / or preventing the indoor conduction block caused by diabetes, and the method is excellent in safety and effectiveness.

A medical device system delivers ventricular pacing pulses as conduction system pacing (CSP) pulses in at least one example. The medical device system senses at least one cardiac electrical signal and obtains at least one post-pace T-wave from the at least one cardiac electrical signal sensed following a delivered CSP pulse. The medical device system may determine at least one T-wave match metric between the at least one post-pace T-wave and at least one T-wave template and determine that effective CSP criteria corresponding to capture of at least a portion of a cardiac conduction system are not met based on the at least one T-wave match metric.